Dare Bioscience Inc. (NASDAQ:DARE) has a beta value of 1.22 and has seen 0.91 million shares traded in the recent trading session. The company, currently valued at $96.28M, closed the recent trade at $1.27 per share which meant it gained $0.11 on the day or 9.39% during that session. The DARE stock price is -48.03% off its 52-week high price of $1.88 and 35.43% above the 52-week low of $0.82. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.25 million shares traded. The 3-month trading volume is 234.16K shares.
The consensus among analysts is that Dare Bioscience Inc. (DARE) is a Buy stock at the moment, with a recommendation rating of 2.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 5 have rated it as a Hold, with 5 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.13.
Dare Bioscience Inc. (NASDAQ:DARE) trade information
Sporting 9.39% in the green today, the stock has traded in the red over the last five days, with the highest price hit on Tuesday, 01/24/23 when the DARE stock price touched $1.27 or saw a rise of 4.51%. Year-to-date, Dare Bioscience Inc. shares have moved 39.76%, while the 5-day performance has seen it change -0.85%. Over the past 30 days, the shares of Dare Bioscience Inc. (NASDAQ:DARE) have changed 34.73%. Short interest in the company has seen 1.36 million shares shorted with days to cover at 5.53.
Wall Street analysts have a consensus price target for the stock at $5.00, which means that the shares’ value could jump 74.6% from the levels at last check today. The projected low price target is $3.00 while the price target rests at a high of $7.00. In that case, then, we find that the latest price level in today’s session is -451.18% off the targeted high while a plunge would see the stock gain -136.22% from the levels at last check today.
Dare Bioscience Inc. (DARE) estimates and forecasts
Figures show that Dare Bioscience Inc. shares have outperformed across the wider relevant industry. The company’s shares have gained 5.45% over the past 6 months, with this year growth rate of 49.21%, compared to 4.50% for the industry. Other than that, the company has, however, increased its growth outlook for the 2023 fiscal year revenue. Growth estimates for the current quarter are 27.80% and 60.00% for the next quarter.
1 have an estimated revenue figure of $5.6 million for the next quarter concluding in Mar 2023.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 4.70% over the past 5 years.
Dare Bioscience Inc. is expected to release its next earnings report between March 29 and April 03 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Dare Bioscience Inc. (NASDAQ:DARE)’s Major holders
Insiders own 1.96% of the company shares, while shares held by institutions stand at 9.31% with a share float percentage of 9.49%. Investors are also buoyed by the number of investors in a company, with Dare Bioscience Inc. having a total of 36 institutions that hold shares in the company. The top two institutional holders are Vanguard Group, Inc. (The) with over 3.53 million shares worth more than $4.45 million. As of Sep 29, 2022, Vanguard Group, Inc. (The) held 4.17% of shares outstanding.
The other major institutional holder is Geode Capital Management, LLC, with the holding of over 0.82 million shares as of Sep 29, 2022. The firm’s total holdings are worth over $1.03 million and represent 0.97% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of Sep 29, 2022, the former fund manager holds about 2.80% shares in the company for having 2.38 million shares of worth $2.99 million while later fund manager owns 0.96 million shares of worth $1.2 million as of Sep 29, 2022, which makes it owner of about 1.13% of company’s outstanding stock.